The causal relationship between gastro-oesophageal reflux disease and idiopathic pulmonary fibrosis: a bidirectional two-sample Mendelian randomisation study
- PMID: 37080571
- PMCID: PMC10209472
- DOI: 10.1183/13993003.01585-2022
The causal relationship between gastro-oesophageal reflux disease and idiopathic pulmonary fibrosis: a bidirectional two-sample Mendelian randomisation study
Abstract
Background: Gastro-oesophageal reflux disease (GORD) is associated with idiopathic pulmonary fibrosis (IPF) in observational studies. It is not known if this association arises because GORD causes IPF or because IPF causes GORD, or because of confounding by factors, such as smoking, associated with both GORD and IPF. We used bidirectional Mendelian randomisation (MR), where genetic variants are used as instrumental variables to address issues of confounding and reverse causation, to examine how, if at all, GORD and IPF are causally related.
Methods: A bidirectional two-sample MR was performed to estimate the causal effect of GORD on IPF risk and of IPF on GORD risk, using genetic data from the largest GORD (78 707 cases and 288 734 controls) and IPF (4125 cases and 20 464 controls) genome-wide association meta-analyses currently available.
Results: GORD increased the risk of IPF, with an OR of 1.6 (95% CI 1.04-2.49; p=0.032). There was no evidence of a causal effect of IPF on the risk of GORD, with an OR of 0.999 (95% CI 0.997-1.000; p=0.245).
Conclusions: We found that GORD increases the risk of IPF, but found no evidence that IPF increases the risk of GORD. GORD should be considered in future studies of IPF risk and interest in it as a potential therapeutic target should be renewed. The mechanisms underlying the effect of GORD on IPF should also be investigated.
Copyright ©The authors 2023.
Conflict of interest statement
Conflict of interest: R.G. Jenkins reports grants from AstraZeneca, Biogen, Galecto, GlaxoSmithKline, RedX, Pliant and Genetech, consulting fees from Bristol-Myers Squibb, Daewoong, Veracyte, Resolution Therapeutics, RedX, Pliant and Chiesi, and advisory board participation with Boehringer Ingelheim, Galapagos, Vicore and Roche, outside the submitted work, and has a leadership role with NuMedii, and a leadership role and is a trustee for Action for Pulmonary Fibrosis. T.M. Maher reports consulting fees from Boehringer Ingelheim, Roche/Genentech, AstraZeneca, Bayer, Blade Therapeutics, Bristol-Myers Squibb, Galapagos, Galecto, GlaxoSmithKline, IQVIA, Pliant, Respivant, Theravance and Veracyte, and lecture honoraria from Boehringer Ingelheim and Roche/Genentech, outside the submitted work. P.L. Molyneaux reports grants from AstraZeneca, consulting fees from Hoffman-La Roche, Boehringer Ingelheim, Trevi, Redex and AstraZeneca, and lecture honoraria from Boehringer Ingelheim and Hoffman-La Roche, outside the submitted work. L.V. Wain reports grants from Orion Pharma, GlaxoSmithKline, Genentech and AstraZeneca, consulting fees from Galapagos and Boehringer Ingelheim, travel support from Genentech, and advisory board participation with Galapagos, outside the submitted work; and is an Associate Editor for the European Respiratory Journal. All other authors have nothing to disclose.
Figures



Comment in
-
The relationship between gastro-oesophageal reflux and pulmonary fibrosis: a never-ending story.Eur Respir J. 2023 May 25;61(5):2300566. doi: 10.1183/13993003.00566-2023. Print 2023 May. Eur Respir J. 2023. PMID: 37230505 No abstract available.
-
Reply: Confounding in Mendelian randomisation studies.Eur Respir J. 2023 Jul 20;62(1):2300995. doi: 10.1183/13993003.00995-2023. Print 2023 Jul. Eur Respir J. 2023. PMID: 37474152 Free PMC article.
-
Confounding is a risk for all observational designs.Eur Respir J. 2023 Jul 20;62(1):2300687. doi: 10.1183/13993003.00687-2023. Print 2023 Jul. Eur Respir J. 2023. PMID: 37474153 No abstract available.
-
Confounding cannot be ignored in any observational design.Eur Respir J. 2023 Jul 20;62(1):2300732. doi: 10.1183/13993003.00732-2023. Print 2023 Jul. Eur Respir J. 2023. PMID: 37474154 No abstract available.
Similar articles
-
Mendelian randomization analysis suggests no causal influence of gastroesophageal reflux disease on the susceptibility and prognosis of idiopathic pulmonary fibrosis.BMC Pulm Med. 2023 Dec 21;23(1):517. doi: 10.1186/s12890-023-02788-8. BMC Pulm Med. 2023. PMID: 38129814 Free PMC article.
-
Genetic liability to gastro-esophageal reflux disease, obesity, and risk of idiopathic pulmonary fibrosis.Respir Investig. 2023 May;61(3):335-338. doi: 10.1016/j.resinv.2023.02.005. Epub 2023 Mar 16. Respir Investig. 2023. PMID: 36933281
-
Gastroesophageal reflux and antacid therapy in IPF: analysis from the Australia IPF Registry.BMC Pulm Med. 2019 May 3;19(1):84. doi: 10.1186/s12890-019-0846-2. BMC Pulm Med. 2019. PMID: 31053121 Free PMC article.
-
Genetic liability of gut microbiota for idiopathic pulmonary fibrosis and lung function: a two-sample Mendelian randomization study.Front Cell Infect Microbiol. 2024 May 22;14:1348685. doi: 10.3389/fcimb.2024.1348685. eCollection 2024. Front Cell Infect Microbiol. 2024. PMID: 38841114 Free PMC article.
-
Decoding the complexity: mechanistic insights into comorbidities in idiopathic pulmonary fibrosis.Eur Respir J. 2025 May 22;65(5):2402418. doi: 10.1183/13993003.02418-2024. Print 2025 May. Eur Respir J. 2025. PMID: 40180336 Free PMC article. Review.
Cited by
-
Higher body mass index was associated with a lower mortality of idiopathic pulmonary fibrosis: a meta-analysis.J Health Popul Nutr. 2024 Aug 16;43(1):124. doi: 10.1186/s41043-024-00620-5. J Health Popul Nutr. 2024. PMID: 39152474 Free PMC article.
-
Causal relationship between gut microbiota and metabolic syndrome: A bidirectional Mendelian randomization study.Medicine (Baltimore). 2025 Apr 25;104(17):e42179. doi: 10.1097/MD.0000000000042179. Medicine (Baltimore). 2025. PMID: 40295236 Free PMC article.
-
Mendelian randomization analysis suggests no causal influence of gastroesophageal reflux disease on the susceptibility and prognosis of idiopathic pulmonary fibrosis.BMC Pulm Med. 2023 Dec 21;23(1):517. doi: 10.1186/s12890-023-02788-8. BMC Pulm Med. 2023. PMID: 38129814 Free PMC article.
-
Progress in understanding and treating idiopathic pulmonary fibrosis: recent insights and emerging therapies.Front Pharmacol. 2023 Aug 7;14:1205948. doi: 10.3389/fphar.2023.1205948. eCollection 2023. Front Pharmacol. 2023. PMID: 37608885 Free PMC article. Review.
-
Associations Between Gut Microbiota and Diabetic Nephropathy: A Mendelian Randomization Study.Aging Med (Milton). 2025 Feb 18;8(1):e70009. doi: 10.1002/agm2.70009. eCollection 2025 Feb. Aging Med (Milton). 2025. PMID: 39968006 Free PMC article.
References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical